INmune Bio Inc. (INMB) Stock: Why It’s Gaining In Value


INmune Bio Inc. (INMB) is trending up in the market in today’s trading session. The company, focused in the biotech space, is currently trading at $10.73 after heading up 5.09% so far today. In terms of biotechnology stocks, there are a number of aspects that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around INMB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 08:30AM INmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast
Jun-10-19 01:35PM INMB: TNF- Inhibition Associated with Decreased Risk of Developing Alzheimers Disease
Jun-04-19 04:45PM INmune Bio to present Alzheimers Drug Candidate XPro1595 at The TNF Conference
May-28-19 09:03AM INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th
May-22-19 10:00AM INMB: Two Additional Clinical Trials Set to Initiate in 2019

However, any time investors are making a decision with regard to investing, investors should focus on much more than news, this is especially the case in the generally speculative biotech sector. Here’s what’s happening in regard to INmune Bio Inc..

What We’ve Seen From INMB

Although a move up on a single session, like the gain that we’re seeing from INmune Bio Inc. might cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to dig into trends experienced by the stock for a period longer than a single trading session. In the case of INMB, here are the returns on investment that investors have experienced:

  • Past 5 Sessions – Throughout the past 7 days, INMB has seen a change in price amounting to 4.47%.
  • Past Month – The monthly returns from INmune Bio Inc. works out to -1.83%.
  • Past Quarter – Over the last quarter, the company has produced a return on investment of 43.07%
  • Past 6 Months – Over the last 6 months, investors have seen a change that works out to 0 from the stock.
  • Year To Date – Since the the first trading session of this year INMB has generated a return on investment of 34.29%.
  • Full Year – Lastly, in the last full year, we have seen performance in the amount of 0 from INMB. Over this period of time, the stock has traded at a high of -6.70% and a low price of 53.29%.

Ratios Of Note

Digging into various ratios associated with a company can provide investors a view of just how dangerous and/or potentially profitable a an investment option might be. Here are a few of the key ratios to think about when looking at INMB.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it means that more investors are expecting that the value of the stock is going to tumble. In general, biotechnology stocks can come with a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, in regard to INmune Bio Inc., it’s short ratio is 0.91.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can pay for its debts when they mature based on quick assets or current assets. In the biotech sector, several companies are heavily reliant on continued investor support, the quick and current ratios can be damning. However, some gems in the biotechnology sector come with strong current and quick ratios. As far as INMB, the quick and current ratios total up to 9.10 and 9.10 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. In this case, that ratio is 2.44.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Several early stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a biotechnology stock, this is a very important ratio to look into. In the case of INMB, the cash to share value ratio comes to 0.58.

How Analysts Feel About INmune Bio Inc.

While it’s not a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their analysis when validating your own opinions before making investment decisions in the biotech sector. Here are the recent moves that we have seen from analysts as it relates to INMB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested In INmune Bio Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in INMB, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutions own 7.30% of the company. On the other hand, it is worth noting that the ownership held by institutions has seen a move of 6.37% throughout the past quarter.
  • Investors On The Inside – When it comes to insiders, those close to the situation currently hold 61.30% of the company. Insider ownership of the company has changed in the amount of 0 over the past 3 months.

Looking At Share Counts

Investors and traders seem to like to know the total numbers of shares both available and outstanding. In terms of INmune Bio Inc., there are currently 10.29M and there is a float of 3.81M. These data mean that out of the total of 10.29M shares of INMB in existence today, 3.81M are able to be traded by the public.

I also find it important to look at the short percent. After all, if a large percentage of the float is sold short, the overall opinion among traders is that the stock is headed for a steep decline. As far as it relates to INMB, the percentage of the float that is sold short comes to a total of 0.45%. In general, high short percent of the float would be considered to be anything over 40%. Nonetheless, I have calculated that anything over 26% is probably going to be a a play that could prove to be very risky.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.03. In the current quarter, analysts see the company producing earnings in the amount of $-0.19. Over the last 5 years, INMB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 30.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here